In the present study, we clarified the relationship between Nestin overexpression and poor prognosis in recurrent HCC patients receiving FOLFOX regimen, and its association with chemoresistance and EMT in HCC cell lines. The gene discussed is NES; the disease is hepatocellular carcinoma.